Iftekhar Ahmed: Global Healthcare Strategist, Empowering People and Transforming Leadership at Danaher

Iftekhar Ahmed is a global business leader with over two decades of experience in healthcare. As Vice President, Global Strategic Markets at Danaher Corporation, Ahmed leads global diagnostics and life sciences strategies. With a proven track record of reshaping organizations and delivering sustainable growth, Ahmed is known for his strategic clarity, cultural fluency, and people-centered leadership style. He believes in empowering people and leading with both precision and heart to drive transformation in the global healthcare ecosystem.

Analysts have lowered their price targets for Danaher Corporation (NYSE: DHR), with HSBC and Deutsche Bank setting new targets of $240.00 and $235.00, respectively [1]. Despite the downward revision, the consensus rating remains a "Moderate Buy". Danaher reported earnings of $1.80 per share for the last quarter, surpassing estimates, with a revenue of $5.94 billion, marking a 3.4% year-over-year increase.

Institutional investor Dillon & Associates Inc. has reduced its holdings in Danaher by 2.9% in the first quarter, according to its latest filing with the SEC [1]. The institutional investor owned 48,099 shares of Danaher's stock after selling 1,416 shares during the period. Danaher accounts for approximately 1.5% of Dillon & Associates Inc.'s holdings, making the stock its 21st biggest position. Dillon & Associates Inc.'s holdings in Danaher were worth $9,860,000 at the end of the most recent quarter.

Other institutional investors have also made adjustments to their holdings in Danaher. Fayez Sarofim & Co lifted its stake by 0.6% in the 4th quarter, Coastal Bridge Advisors LLC by 4.8%, and MGO One Seven LLC by 1.3% [1]. Hedge funds and other institutional investors own 79.05% of the company's stock.

Several research analysts have also revised their target prices for Danaher. HSBC decreased their price target from $270.00 to $240.00, while Deutsche Bank Aktiengesellschaft lowered its target from $240.00 to $235.00 [1]. Evercore ISI decreased its target from $230.00 to $226.00 and set an "outperform" rating on the stock. The Goldman Sachs Group decreased its target from $260.00 to $240.00 and set a "neutral" rating. Royal Bank Of Canada reissued an "outperform" rating and issued a $250.00 target price.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segment offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics [2].

References:
[1] https://www.marketbeat.com/instant-alerts/filing-dillon-associates-inc-cuts-stock-position-in-danaher-corporation-nysedhr-2025-08-11/
[2] https://www.prnewswire.com/news-releases/mihin-responds-to-cms-health-tech-ecosystem-initiative-with-strategic-optimism-and-renewed-commitment-to-community-based-interoperability-302527087.html